References
- 1. UMANATH K., LEWIS JB., Update on Diabetic Nephropathy: Core Curriculum 2018, Am. J. Kidney. Dis., 2018, 71(6):884–895.
- 2. PUGLIESE G., PENNO G., NATALI A., BARUTTA F., DI PAOLO S., REBOLDI G. et al., Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”, J. Nephrol., 2020, 33(1):9–35.
- 3. PERSSON F., ROSSING P., Diagnosis of diabetic kidney disease: state of the art and future perspective, Kidney. Int. Suppl (2011), 2018, 8(1):2–7.
- 4. UWAEZUOKE SN., The role of novel biomarkers in predicting diabetic nephropathy: a review, Int. J. Nephrol. Renovasc. Dis., 2017, 10:221–231.
- 5. LEE SY., CHOI ME., Urinary biomarkers for early diabetic nephropathy: beyond albuminuria, Pediatr. Nephrol., 2015, 30(7):1063–1075.
- 6. DAI H., LIU Q., LIU B., Research Progress on Mechanism of Podocyte Depletion in Diabetic Nephropathy., J. Diabetes. Res., 2017, 2017:2615286.
- 7. LIAPIS H., ROMAGNANI P., ANDERS HJ., New insights into the pathology of podocyte loss: mitotic catastrophe., Am. J. Pathol. 2013, 183(5):1364–1374.
- 8. MATOVINOVIC MS., 3. Podocyte Injury in Glomerular Diseases., EJIFCC, 2009, 20(1):21–27.
- 9. NAKAMURA T., USHIYAMA C., SUZUKI S., HARA M., SHIMADA N.,EBIHARA I. et al., Urinary excretion of podocytes in patients with diabetic nephropathy, Nephrol. Dial. Transplant., 2000, 15:1379–1383.
- 10. WEIL EJ., LEMLEY KV., MASON CC., YEE B., JONES LI., BLOUCH K. et al., Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy, Kidney. Int., 2012, 82(9):1010–1017.
- 11. FISHEA T., Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients, Biomark. Res., 2015, 3:16.
- 12. NAUTA FL., BOERTIEN WE., BAKKER SJL., GOOR HV., OEVEREN WV., YONG PE. et al., Glomerular and tubular damage markers are elevated in patients with diabetes, Diabetes. Care., 2011, 34:975–981.
- 13. KANDASAMY Y., SMITH R., LUMBERS ER., RUDD D., Nephrin – a biomarker of early glomerular injury, Biomark. Res., 2014, 2:21.
- 14. SEKULIC M., SEKULIC PS., A compendium of urinary biomarkers indicative of glomerular podocytopathy, Pathol. Res. Int., 2013, 2013:782395.
- 15. GLUHOVSCHI C., GLUHOVSCHI G., PETRICA L., TIMAR R., VELCIOV S., IONITA I. et al., Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy, J. Diabetes. Res., 2016, 2016:4626125.
- 16. REISER J., ALTINTAS MM., Podocytes, F1000Res, 2016, 5:F1000 Faculty Rev-114.
- 17. NIELSEN J., MCNAGNY K., The Role of Podocalyxin in Health and Disease, J. Am. Soc. Nephrol., 2009, 20(8):1669–1676.
- 18. KOSTOVSKA I., TRAJKOVSKA TK., CEKOVSKA S., SPASOVSKI G., LABUDOVIC D., Nephrin and Podocalyxin – New Podocyte Proteins for Early Detection of Secondary Nephropathies, BANTAO J., 2016, 14(1):11–16.
- 19. SUN D., ZHAO X., MENG L., Relationship between urinary podocytes and kidney diseases, Ren. Fail. 2012, 34(3):403–407.
- 20. AGARWAL R., Diabetic nephropathy, proteinuria, and progression of CKD, Clin. J. Am. Soc. Nephrol., 2009, 4:1523–1528.
- 21. KDIGO., Chapter 1: Definition and classification of CKD, Kidney. Int. Suppl., 2013, 3:19.
- 22. COCKROFT DW., GAULT MH., Prediction of creatinine clearance from serum creatinine, Nephron., 1976, 16:31–41.
- 23. NAVRA AS., BILOUS RW., Laboratory Assessment of Diabetic Kidney Disease, Diabetes. Spectr., 2015, 28(3):162–166.
- 24. ŠIMUNDIC AM., Measures of Diagnostic Accuracy: Basic Definitions, EJIFCC., 2009, 19(4):203–211.
- 25. HABIBZADEH F., HABIBZADEH P., YADOLLAHIE M., On determining the most appropriate test cut-off value: the case of tests with continuous results, Biochem. Med., 2016, 26(3):297–307.
- 26. CHIDA S., FUJITA Y., OGAWA A., HAYASHI A., ICHIKAWA R., HAYASHI A. et al., Levels of albuminuria and risk of developing macroalbuminuria in type 2 diabetes: historical cohort study, Sci. Rep., 2016, 6:26380.
- 27. El-SAEED GK., SHEHAB El-DEEN WA., MONTASR BA., OMAR TA., MOHAMED DS., Urinary podocalyxin and cyclophilin A: markers for early detection of type 2 diabetic nephropathy, Menoufia. Med. J., 2019, 32:996–1003.
- 28. Al-RUBEAAN K., SIDDIQUI K., Al-GHONAIM MA., YOUSSEF AM., Al-SHARQAWI AH., AlNAQEB D., Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients, Sci. Rep., 2017, 7(1):2684.
- 29. YE H., BAI X., GAO H., LI L., WU C., SUN X. et al., Urinary podocalyxin positive-element occurs in the early stage of diabetic nephropathy and is correlated with a clinical diagnosis of diabetic nephropathy, J. Diabetes. Complicat., 2014, 28:96–100.
- 30. HARA M., YAMAGATA K., TOMINO Y., SAITO A., HIRAYAMA Y., OGASAWARA S. et al., Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin, Diabetologia., 2012, 55(11):2913–2919.
- 31. SHOJI M., KOBAYASHI K., TAKEMOTO M., SATO Y., YOKOTE K., Urinary podocalyxin levels were associated with urinary albumin levels among patients with diabete, Biomarkers., 2016, 21(2):164–167.
- 32. WANG R.,YAO C., LIU F., Association between Renal Podocalyxin Expression and Renal Dysfunction in Patients with Diabetic Nephropathy: A Single-Center, Retrospective Case-Control Study, BioMed. Res. Int., 2020, Article ID 7350781.
- 33. BACCI MR., CHEHTER EZ., AZZALIS LA, COSTA DE AGUIAR ALVES B., FONCESKA FLA., Serum NGAL and Cystatin C Comparison With Urinary Albumin-to-Creatinine Ratio and Inflammatory Biomarkers as Early Predictors of Renal Dysfunction in Patients With Type 2 Diabetes, Kidney. Int. Rep., 2016, 2(2):152–158.